Australia's most trusted source of pharma news
Who topped PBAC in 2017?
Posted 7 March 2018
Roche finished 2017 with three initial major submissions and one resubmission recommended by the PBAC in a year when more sponsors saw rejection than recommendation.
A data snapshot of the year by consultancy business Commercial Eyes found that while more than 50 per cent of the 178 PBAC decisions made last year were positive recommendations, the bulk was for minor submissions.
In contrast, major submissions were more likely to meet rejection than recommendation at all three of the PBAC's major meetings in 2017, which included the April, August and December special meetings. Deferrals were also higher for major submissions.
Minor submissions made up 52 per cent of all PBAC submissions compared to 48 per cent for major submissions.
The snapshot also noted that 10 out of the 59 sponsors that made a PBAC submission in 2017 were responsible for almost half of all submissions, with MSD and Roche leading the way at 10 each.
MSD's high number was pushed up by five submissions for its blockbuster Keytruda, which was also the drug with the highest number of outcomes published during the period.
Rival checkpoint inhibitor Opdivo received four outcomes making it the second highest number for a single drug. Both drugs, however, received only one positive recommendation in 2017 from their multiple attempts.
Roche drugs which were submitted to the PBAC in 2017 included Ocrevus, Tecentriq, and Alecensa, all of which received positive recommendations for new listings making Roche the most successful sponsor. The company also received positive recommendations for extended uses of MabThera and Pegasys.
Janssen lodged nine submissions while AbbVie, Novartis, and nutritional formula specialists Nutricia and Vitaflo lodged seven each.
BI and Celgene lodged six submissions each while Pfizer came in at number 10 with five submissions.
Oncology was by far the biggest therapeutic area with 32 per cent of submissions lodged being for cancer therapies.
Diabetes took 10 per cent of the submitted indications while respiratory illnesses made up six per cent.
Yajun Ma
Posted 7 March 2018
Roche finished 2017 with three initial major submissions and one resubmission recommended by the PBAC in a year when more sponsors saw rejection than recommendation.
A data snapshot of the year by consultancy business Commercial Eyes found that while more than 50 per cent of the 178 PBAC decisions made last year were positive recommendations, the bulk was for minor submissions.
In contrast, major submissions were more likely to meet rejection than recommendation at all three of the PBAC's major meetings in 2017, which included the April, August and December special meetings. Deferrals were also higher for major submissions.
Minor submissions made up 52 per cent of all PBAC submissions compared to 48 per cent for major submissions.
The snapshot also noted that 10 out of the 59 sponsors that made a PBAC submission in 2017 were responsible for almost half of all submissions, with MSD and Roche leading the way at 10 each.
MSD's high number was pushed up by five submissions for its blockbuster Keytruda, which was also the drug with the highest number of outcomes published during the period.
Rival checkpoint inhibitor Opdivo received four outcomes making it the second highest number for a single drug. Both drugs, however, received only one positive recommendation in 2017 from their multiple attempts.
Roche drugs which were submitted to the PBAC in 2017 included Ocrevus, Tecentriq, and Alecensa, all of which received positive recommendations for new listings making Roche the most successful sponsor. The company also received positive recommendations for extended uses of MabThera and Pegasys.
Janssen lodged nine submissions while AbbVie, Novartis, and nutritional formula specialists Nutricia and Vitaflo lodged seven each.
BI and Celgene lodged six submissions each while Pfizer came in at number 10 with five submissions.
Oncology was by far the biggest therapeutic area with 32 per cent of submissions lodged being for cancer therapies.
Diabetes took 10 per cent of the submitted indications while respiratory illnesses made up six per cent.
Yajun Ma
Drought, fire and now virus cut chance of PBS relief.
Don't do it for the accolades; do it for your kids.
New forms of rotavirus vaccine Rotarix.